Corcept Therapeutics Inc
A California drugmaker that tames the stress hormone cortisol, which the body pumps out in excess in some illnesses. Its best-known medicine, Korlym, treats Cushing's syndrome, a condition where too much cortisol causes high blood sugar and other troubles. Founded in 1998 by two Stanford psychiatrists, the company got its name from a mashup of "cortisol" and "concept." Its founding idea grew out of a Stanford researcher's hunch that the abortion pill mifepristone could also block cortisol's effects — a hunch that later became its flagship drug.
Granted 1.80M · Sold 735.0K
Granted 140.0K · Bought 100.0K
Granted 650.0K · Sold 10.0K
Granted 150.0K · Sold 72.4K
Granted 550.0K · Sold 20.5K
Granted 959.6K · Sold 846.8K
Granted 717.5K · Sold 340.0K
Granted 99.3K · Sold 80.0K
Granted 430.2K · Sold 429.0K
Granted 346.0K · Sold 336.4K
Granted 82.7K · Sold 78.0K
Granted 11.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Belanoff Joseph KChief Executive Officer, Director · 48 transactions | — | 6.36M | 1.80M | — | 735.0K |
| Baker G Leonard JrDirector · 14 transactions | +5.3% | 5.53M | 140.0K | 100.0K | — |
| Wilson James NDirector · 29 transactions | — | 2.82M | 650.0K | — | 10.0K |
| Mahoney David LDirector · 24 transactions | — | 2.55M | 150.0K | — | 72.4K |
| Hunt HazelChief Scientific Officer · 15 transactions | +270.3% | 255.4K | 550.0K | — | 20.5K |
| Maduck SeanSee Remarks · 171 transactions | — | 137.7K | 959.6K | — | 846.8K |
| Robb Gary CharlesChief Business Officer · 144 transactions | — | 125.0K | 717.5K | — | 340.0K |
| Mokari AtabakChief Financial Officer · 47 transactions | — | 56.1K | 99.3K | — | 80.0K |
| Guyer WilliamChief Development Officer · 89 transactions | — | 29.5K | 430.2K | — | 429.0K |
| Lyon Joseph DouglasSee Remarks · 117 transactions | -71.9% | 7.0K | 346.0K | — | 336.4K |
| Swisher Daniel N JRDirector · 61 transactions | -70.7% | 2.2K | 82.7K | — | 78.0K |
| Cannon GillianDirector · 3 transactions | — | 0 | 11.0K | — | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 5 years: -2.85M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.